Considering popular SGLT‐2 inhibitor agents used globally (ie canagliflozin, dapagliflozin and empagliflozin), most cancer‐related data collected for these individual agents also indicated there were no significant associations between their use and overall risk of any cancer event. Here, SLC5A2 is linked to cancer.